These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 36262014)

  • 1. An overview of mineralocorticoid receptor antagonists as a treatment option for patients with heart failure: the current state-of-the-art and future outlook.
    Lorente-Ros M; Aguilar-Gallardo JS; Shah A; Narasimhan B; Aronow WS
    Expert Opin Pharmacother; 2022 Oct; 23(15):1737-1751. PubMed ID: 36262014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Mineralocorticoid Receptor Antagonists in Heart Failure with Preserved Ejection Fraction and with Reduced Ejection Fraction - A Narrative Review.
    Mares A; Rodriguez T; Deoker A; Lehker A; Mukherjee D
    Curr Vasc Pharmacol; 2022; 20(1):46-51. PubMed ID: 34303331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
    Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
    Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
    Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of mineralocorticoid receptor antagonists on left ventricular diastolic function, exercise capacity, and quality of life in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials.
    Fukuta H; Goto T; Wakami K; Kamiya T; Ohte N
    Heart Vessels; 2019 Apr; 34(4):597-606. PubMed ID: 30315496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis.
    Berbenetz NM; Mrkobrada M
    BMC Cardiovasc Disord; 2016 Dec; 16(1):246. PubMed ID: 27905877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction.
    Papademetriou V; Toumpourleka M; Imprialos KP; Alataki S; Manafis A; Stavropoulos K
    Curr Pharm Des; 2018; 24(46):5517-5524. PubMed ID: 30806305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of the Mineralocorticoid Receptor and Mineralocorticoid Receptor-Directed Therapies in Heart Failure.
    Young MJ; Kanki M; Karthigan N; Konstandopoulos P
    Endocrinology; 2021 Nov; 162(11):. PubMed ID: 34050730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction.
    Serenelli M; Jackson A; Dewan P; Jhund PS; Petrie MC; Rossignol P; Campo G; Pitt B; Zannad F; Ferreira JP; McMurray JJV
    JACC Heart Fail; 2020 Mar; 8(3):188-198. PubMed ID: 31926854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials.
    Kapelios CJ; Murrow JR; Nührenberg TG; Montoro Lopez MN
    Heart Fail Rev; 2019 May; 24(3):367-377. PubMed ID: 30618017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials.
    Yang P; Shen W; Chen X; Zhu D; Xu X; Wu T; Xu G; Wu Q
    Heart Fail Rev; 2019 Sep; 24(5):637-646. PubMed ID: 31030322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical Therapies for Heart Failure With Preserved Ejection Fraction.
    Kjeldsen SE; von Lueder TG; Smiseth OA; Wachtell K; Mistry N; Westheim AS; Hopper I; Julius S; Pitt B; Reid CM; Devereux RB; Zannad F
    Hypertension; 2020 Jan; 75(1):23-32. PubMed ID: 31786973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
    Marzolla V; Infante M; Armani A; Rizzo M; Caprio M
    Expert Opin Drug Saf; 2022 Sep; 21(9):1161-1170. PubMed ID: 36174659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should MRAs be at the front row in heart failure? A plea for the early use of mineralocorticoid receptor antagonists in medical therapy for heart failure based on clinical experience.
    Heggermont WA; Goethals M; Dierckx R; Verstreken S; Bartunek J; Vanderheyden M
    Heart Fail Rev; 2016 Nov; 21(6):699-701. PubMed ID: 27620301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone.
    Rico-Mesa JS; White A; Ahmadian-Tehrani A; Anderson AS
    Curr Cardiol Rep; 2020 Sep; 22(11):140. PubMed ID: 32910349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: A systematic review and meta-analysis.
    Pei H; Wang W; Zhao D; Wang L; Su GH; Zhao Z
    Medicine (Baltimore); 2018 Apr; 97(16):e0254. PubMed ID: 29668577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure.
    Pitt B; Rossignol P
    Expert Opin Drug Saf; 2016 May; 15(5):659-65. PubMed ID: 26958701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT).
    Fudim M; Kelly JP; Brophy TJ; DeVore AD; Hammill BG; Peterson ED; Pitt B; Yancy C; Fonarow GC; Hernandez AF
    Am J Cardiol; 2020 Jun; 125(11):1655-1660. PubMed ID: 32273054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
    Martin N; Manoharan K; Davies C; Lumbers RT
    Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.
    Agarwal R; Kolkhof P; Bakris G; Bauersachs J; Haller H; Wada T; Zannad F
    Eur Heart J; 2021 Jan; 42(2):152-161. PubMed ID: 33099609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.